Jun 2, 2026 08:02AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM
May 28, 2026 09:18PM
May 28, 2026 12:42PM
May 27, 2026 04:04AM
May 22, 2026 10:17AM DATROWAY approved in US for first-line metastatic triple-negative breast cancer
May 22, 2026 10:16AM
May 22, 2026 09:30AM
May 22, 2026 09:30AM
May 22, 2026 08:00AM
May 22, 2026 08:00AM
May 22, 2026 07:00AM
May 22, 2026 07:00AM AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
May 18, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 05:07AM
May 15, 2026 09:52PM
May 15, 2026 06:31PM
May 14, 2026 07:00AM
May 1, 2026 05:44AM FDA Advisory Committee recommends TRUQAP for prostate cancer subtype
Apr 30, 2026 09:42PM
Apr 30, 2026 11:49AM
Apr 28, 2026 01:46PM
Apr 28, 2026 07:03AM
Apr 28, 2026 07:00AM
Apr 27, 2026 07:03AM
Apr 27, 2026 07:00AM SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
Apr 20, 2026 07:01AM
Apr 7, 2026 02:09PM
Apr 2, 2026 07:00AM
Apr 2, 2026 07:00AM
Mar 24, 2026 10:30AM
Mar 9, 2026 08:45AM
Mar 9, 2026 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Mar 9, 2026 02:30AM
Feb 20, 2026 07:01AM
Feb 20, 2026 07:00AM
Feb 19, 2026 05:28AM
Feb 19, 2026 02:30AM
Feb 3, 2026 07:00AM
Feb 3, 2026 07:00AM DATROWAY® (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy
Feb 3, 2026 04:11AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM
Jan 13, 2026 07:00AM
Jan 13, 2026 07:00AM
Dec 22, 2025 07:01AM
Dec 22, 2025 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer
Dec 22, 2025 05:40AM

322,185 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All